ClinicalTrials.gg
Not yet recruitingNCT07640217Updated Jun 10, 2026

A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)

A Phase 2 interventional study of SYH2068 Dose 1 and SYH2068 Dose 2 in Adult Participants With Elevated Lipoprotein(a), sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).

Read the detailed description

This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase II clinical trial aimed at evaluating the efficacy, safety, immunogenicity, and pharmacokinetic characteristics of SYH2068 injection in adult participants with elevated lipoprotein(a). The study consists of a screening period and a treatment period.

02

Conditions studied

  • Adult Participants With Elevated Lipoprotein(a)
03

In context

Lead sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. is the lead sponsor of 30 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants ≥18 years of age;
  2. Elevated Lp(a);
  3. Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs;
  4. Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk;
  5. Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Diseases that significantly affect Lp(a) during screening period,
  2. Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization;
  3. Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period;
  4. class III-IV at the time of signing the ICF or \<40% during the screening period;
  5. Type 1 diabetes or hereditary hemorrhagic disorder at screening;
  6. History of malignant tumor or suspected within 5 years prior to screening;
  7. Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period;
  8. Allergy to oligonucleotide drugs;
  9. Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the drug;
  10. Female participants who are pregnant or breastfeeding at screening, or female / male participants who plan to conceive during the study and within 1 year after the last dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    SYH2068 Dose 1

    Drug: SYH2068 Dose 1

  • Experimental
    SYH2068 Dose 2

    Drug: SYH2068 Dose 2

  • Experimental
    SYH2068 Dose 3

    Drug: SYH2068 Dose 3

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSYH2068 Dose 1

    Administered by subcutaneous injection.

  • DrugSYH2068 Dose 2

    Administered by subcutaneous injection.

  • DrugSYH2068 Dose 3

    Administered by subcutaneous injection.

  • DrugPlacebo

    Administered by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percentage change in Lp(a) from baseline to Day 60~180

    Time frame: Day 60~180

Secondary outcomes

  1. Percentage change in Lp(a) from baseline to Day 30~540

    Time frame: Day 30~540

  2. The percentage of participants achieving Lp(a) < 125 nmol/L and <75 nmol/L.

    Time frame: Day 30~540

  3. Changes of LDL-C from baseline to Day 30~540

    Time frame: Day 30~540

  4. Changes of ApoB from baseline to Day 30~540

    Time frame: Day 30~540

  5. Incidence of TEAEs during the treatment

    Time frame: During treatment

  6. ADA incidence

    Time frame: During treatment

  7. The plasma concentration of SYH2068.

    Time frame: During treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Mar 2028, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 10, 2026
StartEst.
Jul 30, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07640217
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Jul 30, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jun 10, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
0311-69085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion